Monday, July 23, 2018

Gossamer Bio Gains $230M

San Diego-based Gossamer Bio, a biotechnology company focused on therapeutics in the autoimmune, allergy/inflammation, and immuno-oncology disease areas, said on Monday that it has raised $230M in a Series B funding round. The massive funding round was led by Hillhouse Capital, and also included a wholly-owned subsidiary of the Abu Dhabi Investment A

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.